Changeflow GovPing Healthcare & Life Sciences Mutated Lacto-N-Biosidase with Improved Propert...
Routine Notice Added Final

Mutated Lacto-N-Biosidase with Improved Properties from Bifidobacterium Longum

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260110008A1 for mutated lacto-N-biosidase enzymes with improved properties derived from Bifidobacterium longum. The application names five inventors: Birgitte Zeuner, Jan Muschiol, Marlene Isabelle Vuillemin, Anne Merete Boye Strunge Meyer, and Jesper Holck. Filing date was December 14, 2023, under application number 19138531. The patent application does not impose compliance obligations but may affect competitive R&D strategy in enzyme biotechnology and related sectors.

“Mutated lacto-N-biosidases are provided with improved properties compared to the wild type lacto-N-biosidase isolated from Bifidobacterium longum.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.

What changed

The USPTO published patent application US20260110008A1 for mutated lacto-N-biosidase enzymes derived from Bifidobacterium longum with improved properties compared to the wild-type enzyme. The application names five inventors and was filed December 14, 2023 under application number 19138531, with CPC classifications in C12P 19/26, C12N 9/2402, and C12Y 302/0114. Patent applications do not create compliance obligations but establish intellectual property rights that may affect competitive R&D strategies in the enzyme biotechnology sector.

For entities in the biotech and pharmaceutical industries, this published application signals potential freedom-to-operate considerations for lacto-N-biosidase enzyme development. Companies developing similar enzyme products should review their own IP portfolios and assess whether the claimed mutations may overlap with their R&D programs. Patent prosecution will continue before any patent grant.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MUTATED LACTO-N-BIOSIDASE

Application US20260110008A1 Kind: A1 Apr 23, 2026

Inventors

Birgitte ZEUNER, Jan MUSCHIOL, Marlene Isabelle VUILLEMIN, Anne Merete Boye Strunge MEYER, Jesper HOLCK

Abstract

Mutated lacto-N-biosidases are provided with improved properties compared to the wild type lacto-N-biosidase isolated from Bifidobacterium longum.

CPC Classifications

C12P 19/26 C12N 9/2402 C12Y 302/0114

Filing Date

2023-12-14

Application No.

19138531

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Research institutions
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Enzyme research Biotech IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!